Alzinova AB is developing an Alzheimer's disease vaccine that uses an engineered beta amyloid mimic to raise an immune response against highly toxic AD-associated beta amyloid oligomers. The approach could yield a more potent protective immune response than prior vaccines aimed at larger fibrillar aggregates of beta amyloid.

Most therapeutic efforts in AD have focused on blocking the production or accumulation of beta amyloid, which over time leads to neurodegeneration and dementia.